First-line asthma therapy requiring inhaled short-acting beta-agonists (SABA) and systemic corticosteroids is well-established and usually effective in most children with mild or moderate exacerbations.¹ However, a minority of children fail to respond and require escalation treatment.¹ With a large

Secukinumab, a fully human monoclonal antibody that selectively targets IL-17A, was the first drug in its class to receive approval for use in patients with ankylosing spondylitis (AS).^1,2 Back in 2016, the U.S. Food and Drug